Q-omics provides the consensus-scored GRIK1 profile across patient tissues and cancer cell-line models. GRIK1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GRIK1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, GRIK1 RNA expression shows 16,863 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight KIRC, HNSC, and SKCM as cancer lineages where GRIK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIK1 survival associations across molecular data types. GRIK1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIK1 RNA expression–survival associations across cancer types. High GRIK1 expression shows unfavorable associations in KIRC, UVM, ACC, KIRP and LGG, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GRIK1 RNA expression.
This table summarizes GRIK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GRIK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIK1 shows lower tumor expression in COAD, BRCA, THCA, READ and STAD and higher tumor expression in HNSC. The HNSC box plot shows higher GRIK1 RNA expression in tumor versus normal tissue (log2 FC = +0.153, t-test p < 0.001).
This table shows molecular features associated with GRIK1 in patient tissues and cancer cell lines. In patient samples, GRIK1 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
